Feb. 2 at 2:53 PM
$BNTX Biontech is not only cash-rich, with over USD 20 billion and stable since the coronavirus pandemic began. During this time, competitors Moderna and Summit have lost significantly more than half of their cash (many billions). Biontech is cash-stable and has achieved more. Every year, Biontech generates significant added value in addition to its income statement. These are “hidden reserves” that are very active in business terms. Around 90% of R&D costs, or around USD 2 billion, are invested in the oncology pipeline, which is not included in the annual profits. Between 2023 and 2025, BioNTech also implemented an impressive billion-dollar M&A strategy (purchase of company shares): DualityBio, OncoC4, MediLink, Autolus, Biotheus, InstaDeep (AI, exaflop), and CureVac. What are these worth in addition to the cash? And over
$1 billion has been invested in setting up sites (worldwide and in Mainz). High-quality equipment and production facilities have been purchased and built. Greatstock
